Jane Street’s Neurogene NGNE Stock Holding History

Jane Street’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$820K	Buy	+26,089	New	+$718K	﹤0.01%	6946
2026 Q1	–	Sell	-15,105	Closed	-$293K	–	12520
2025 Q4	$311K	Sell	15,105 -47,302	-76%	-$1.18M	﹤0.01%	8760
2025 Q3	$1.08M	Buy	+62,407	New	+$1.25M	﹤0.01%	6154
2024 Q4	–	Sell	-7,717	Closed	-$287K	–	10177
2024 Q3	$324K	Buy	+7,717	New	+$299K	﹤0.01%	7909
2024 Q2	–	Sell	-54,888	Closed	-$2.79M	–	9923
2024 Q1	$2.79M	Buy	+54,888	New	+$1.83M	﹤0.01%	3517
2023 Q1	–	Sell	-3,033	Closed	-$30.9K	–	9621
2022 Q4	$30.9K	Buy	+3,033	New	+$31.3K	﹤0.01%	8499
2020 Q3	–	Sell	-2,149	Closed	-$714K	–	7661
2020 Q2	$714K	Buy	2,149 +133	+7%	+$34.7K	﹤0.01%	4554
2020 Q1	$459K	Buy	+2,016	New	+$415K	﹤0.01%	3710
2016 Q4	–	Sell	-784	Closed	-$209K	–	4424
2016 Q3	$209K	Buy	+784	New	+$158K	﹤0.01%	3677
2014 Q4	–	Sell	-1,000	Closed	-$133K	–	2846
2014 Q3	$133K	Buy	+1,000	New	+$152K	﹤0.01%	2315
2014 Q2	–	Sell	-624	Closed	-$159K	–	2935
2014 Q1	$159K	Buy	+624	New	+$160K	﹤0.01%	2430

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Jane Street's NGNE Position: Q2 2026 in Review

Jane Street opened a new position in Neurogene (NGNE) in Q2 2026: 26,089 shares worth $820K. The stake represents ﹤0.01% of the portfolio and ranks #6946 among its holdings. This is a return to the name: Jane Street previously reported a position in NGNE as recently as Q4 2025.

Jane Street first reported a position in NGNE in Q1 2014 and has held it in 11 quarters since. The position peaked at $2.79M in Q1 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

Jane Street held 26,089 shares of Neurogene worth $820K as of Q2 2026.
Neurogene was a new Jane Street position in Q2 2026.
Neurogene made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #6946 holding.
Jane Street first reported a position in Neurogene in Q1 2014 and has held it in 11 quarters since.
Jane Street's Neurogene position peaked at $2.79M in Q1 2024.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.